Abstract:Objectives: 15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) is a natural ligand that activates the peroxisome proliferator-activated receptor (PPAR)-gamma, a member of the nuclear receptor family implicated in the regulation of lipid metabolism and adipocyte differentiation. Recent data have shown that 15d-PGJ2 exerts anti-inflammatory action via inhibition of the interferon gamma (IFN-gamma)-induced Jak-STAT signalling pathway. The anti-inflammatory effect of IL-10 is mediated via activated STAT3 (signal transducer and activator of transcription 3). In this study, we investigated whether 15d-PGJ2 inhibit IL-10-induced STAT activation. Methods: We used western blotting, flow cytometric analysis and a real-time polymerase chain reaction. Results: 15d-PGJ2 blocked IL-10-induced STAT1 and STAT3 activation in primary human monocytes, macrophages and THP-1 cells. Inhibition was not specific for IL-10, as induction of STAT activation by IFN-gamma and IL-6 was also inhibited by 15d-PGJ2. Inhibition of IL-10 signalling was induced within 1 h after pretreatment of 15d-PGJ2. Other PPARgamma agonists, such as troglitazone, did not inhibit IL-10 signalling. Treatment with GW9662, a specific PPARgamma antagonist, had no effect on 15d-PGJ2-mediated inhibition of IL-10 signalling even at higher concentrations (50 microM), indicating that 15d-PGJ2 affects the IL-10-induced Jak-STAT signalling pathway via an PPARgamma-independent mechanism. Actinomycin D had no effect on 15d-PGJ2-mediated inhibition of IL-10 signalling, indicating that inhibition of IL-10 signalling occurs independently of de novo gene expression. Also, inhibitors of extracellular signal-regulated kinase (ERKs) (PD98059), p38 MAPK (mitogen-activated protein kinase) (SB203580) and protein kinase C (PKC) (GF109203X, calphostin C) had no effect on 15d-PGJ2-mediated inhibition of IL-10 signalling. These results show that MAPKs and PKC are not involved in the inhibition of IL-10 signalling. Conclusions: We showed that 15d-PGJ2 non-specifically inhibits STAT signalling of the anti-inflammatory cytokine IL-10 as well as the proinflammatory cytokine IFN-gamma. These findings indicate the possibility that 15d-PGJ2 can have adverse effects in the management of diseases in which IL-10 plays a critical role in the suppression of inflammation.

Inhibition of interleukin-6 signaling by galiellalactone

Expression of Human Alpha-Galactosidase Leads to Reduction of Major Xenoepitope Gal Alpha(1,3) Gal in Nih 3t3 Cell

Enantioselective syntheses and application of 4-epi-galiellalactone and the corresponding activity-based probe: from strained bicycles to strained tricycles

20(S)-25-methoxyl-dammarane-3β, 12β, 20-Triol Negatively Regulates Activation of STAT3 and ERK Pathways and Exhibits Anti-Cancer Effects in HepG2 Cells

15-Deoxy-delta12,14-PGJ2 inhibits IL-6-induced Stat3 phosphorylation in lymphocytes

Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo

Nonspecific Inhibition of IL6 Family Cytokine Signalling by Soluble gp130

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

Structure-based Virtual Screening and Characterization of a Novel IL-6 Antagonistic Compound from Synthetic Compound Database

Function and molecular modeling of the interaction between human interleukin 6 and its HNK-1 oligosaccharide ligands

Bigelovin Inhibits STAT3 Signaling by Inactivating JAK2 and Induces Apoptosis in Human Cancer Cells

Interleukin‐11 receptor is an alternative α‐receptor for interleukin‐6 and the chimeric cytokine IC7

Effect of Interleukin-6 on the Growth of Human Lung Cancer Cell Line.

Isoliquiritigenin Inhibits Interferon-γ-Inducible Genes Expression in Hepatocytes through Down-Regulating Activation of JAK1/STAT1, IRF3/MyD88, ERK/MAPK, JNK/MAPK and PI3K/Akt Signaling Pathways

Searching Interleukin 6 Antagonists by Screening Random Peptide Libraries

EXPERIMENTAL STUDY ON INTERLEUKIN-6 ACTIVITY AGAINST TUMOR: REGULATION OF INTERLEUKIN-2- INDUCED LAK CELL ACTIVITY

Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandin J2

Unveiling novel insights into human IL-6 - IL-6R interaction sites through 3D computer-guided docking and systematic site mutagenesis

Targeting IL-6 trans-signalling: past, present and future prospects

Effects of soluble gp130 and its antisense RNA on activities of target genes induced by IL-6

Acyclic Triterpenoids from Alpinia katsumadai Inhibit IL-6-Induced STAT3 Activation